Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
SYN's Cash to Debt is ranked higher than
93% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. SYN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SYN' s 10-Year Cash to Debt Range
Min: 0.02  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
87% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SYN' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -10.29
M-Score: -19.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -449.23
SYN's ROE (%) is ranked lower than
97% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. SYN: -449.23 )
Ranked among companies with meaningful ROE (%) only.
SYN' s 10-Year ROE (%) Range
Min: -4484.82  Med: -120.20 Max: -48.04
Current: -449.23
-4484.82
-48.04
ROA (%) -238.16
SYN's ROA (%) is ranked lower than
94% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. SYN: -238.16 )
Ranked among companies with meaningful ROA (%) only.
SYN' s 10-Year ROA (%) Range
Min: -1044.06  Med: -111.77 Max: -41.8
Current: -238.16
-1044.06
-41.8
ROC (Joel Greenblatt) (%) -8819.15
SYN's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. SYN: -8819.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SYN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6156.76  Med: -915.08 Max: -112.64
Current: -8819.15
-6156.76
-112.64
EBITDA Growth (3Y)(%) 16.30
SYN's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. SYN: 16.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SYN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 108
Current: 16.3
0
108
EPS Growth (3Y)(%) 4.60
SYN's EPS Growth (3Y)(%) is ranked higher than
61% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. SYN: 4.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SYN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 65.1
Current: 4.6
0
65.1
» SYN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

SYN Guru Trades in Q1 2014

Chuck Royce 276,000 sh (-64.52%)
» More
Q2 2014

SYN Guru Trades in Q2 2014

Chuck Royce 276,000 sh (unchged)
» More
Q3 2014

SYN Guru Trades in Q3 2014

Chuck Royce 276,000 sh (unchged)
» More
Q4 2014

SYN Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Current Ratio 0.89
SYN's Current Ratio is ranked lower than
89% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. SYN: 0.89 )
Ranked among companies with meaningful Current Ratio only.
SYN' s 10-Year Current Ratio Range
Min: 0.03  Med: 6.14 Max: 58.44
Current: 0.89
0.03
58.44
Quick Ratio 0.89
SYN's Quick Ratio is ranked lower than
86% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. SYN: 0.89 )
Ranked among companies with meaningful Quick Ratio only.
SYN' s 10-Year Quick Ratio Range
Min: 0.03  Med: 6.14 Max: 58.44
Current: 0.89
0.03
58.44

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -13.82
SYN's Earnings Yield (Greenblatt) (%) is ranked lower than
69% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. SYN: -13.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SYN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -20.9  Med: 0.00 Max: 0
Current: -13.82
-20.9
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SFYB.Germany,
Synthetic Biologics Inc was incorporated in 1986 as Sheffield Pharmaceuticals, Inc. The Company is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases. Its developing an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome or C-IBS, an oral biologic to protect the gastrointestinal or GI microflora from the effects of intravenous or IV antibiotics for the prevention of Clostridium difficile or C. diff infection, a series of monoclonal antibodies or mAbs for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, it has two legacy programs. Its developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis or MS and cognitive dysfunction in MS. It also partnered the development of a treatment for fibromyalgia. Trimesta or oral estriol is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at UCLA. There are nine FDA-approved therapies for the treatment of relapsing-remitting MS: Betaseron, Rebif, Avonex, Copaxone, Tysabri, Gilenya, Extavia, Aubagio and Tecfidera. Effirma or flupirtine is being developed for the treatment of fibromyalgia by Meda AB. Current FDA-approved therapies for the treatment of C-IBS include AMITIZA or lubiprostone and LINZESS or linaclotide. The Company utilizes contract manufacturing firms to produce its investigational products Trimesta and SYN-004 in accordance with current good manufacturing processes or cGMP guidelines outlined by the FDA. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics, among others. The Company is subject to various government FDA, FTC, CPSC and USDA regulations.
» More Articles for SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
Monday's Mid-Day Movers: Greece's Bank Shuts Down; Puerto Rico Unable To Pay Debts Jun 29 2015
Synthetic Biologics Inc (SYN) Jumps: Is It A Good Stock To Buy? Jun 29 2015
Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with... Jun 29 2015
Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with... Jun 29 2015
Syngenta rebuffs latest offer from Monsanto, saying company 'significantly undervalued' Jun 23 2015
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial... Jun 16 2015
First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the... Jun 12 2015
First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the... Jun 12 2015
Stock Futures Are Slightly Lower as China's Exports Fall Jun 08 2015
Synthetic Biologics Presents Initial Data Validating Platform Expansion to Cover Carbapenem... Jun 03 2015
Synthetic Biologics Presents Initial Data Validating Platform Expansion to Cover Carbapenem... Jun 03 2015
Synthetic Biologics Expands Clinical & Regulatory Leadership Team with Addition of Klaus Gottlieb,... Jun 02 2015
Synthetic Biologics Expands Clinical & Regulatory Leadership Team with Addition of Klaus Gottlieb,... Jun 02 2015
Synthetic Biologics to Host Microbiome Analyst & Investor Meeting Jun 01 2015
Synthetic Biologics to Host Microbiome Analyst & Investor Meeting Jun 01 2015
Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking... May 19 2015
Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking... May 19 2015
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments... May 18 2015
Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster May 18 2015
Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster May 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK